FDA-Issued CRL for Relacorilant NDA Leads to Bullish Views Around Corcept Therapeutics (CORT)

Corcept Therapeutics (NASDAQ:CORT) is one of the 17 biotechnology stocks with more than 50% upside. On February 2, Edward Nash from Canaccord Genuity reaffirmed his Buy rating for Corcept Therapeutics (NASDAQ:CORT). He forecasted a price target of $100, which leads to almost 161% upside potential on the stock. Nestor Rizhniak/Shutterstock.com Nash noted that the CRL issued by the U.S. FDA for the relacorilant NDA confirms their prior expectations. Their model already accounted for the need to conduct a ...